As part of the implementation of the instructions of the President of the Republic of Kazakhstan to increase the share of domestic production in the pharmaceutical industry to 50%, a major strategic investment project will be implemented in Kazakhstan. The corresponding resolution has been signed by Prime Minister Olzhas Bektenov.

The document approves a draft Investment Agreement between the Ministry of Healthcare of the Republic of Kazakhstan and Khan Tengri Biopharma LLP for the construction of a modern manufacturing complex in the Alatau Special Economic Zone.

The facility is planned to be equipped with advanced technologies for the production of medicines. The key objective is the establishment of capacities for the manufacture of 58 types of pharmaceutical products. Special emphasis is placed on launching a full production cycle, including the manufacturing of active pharmaceutical ingredients (APIs).

The production portfolio of the complex will include 27 international nonproprietary names (INNs), including medicines for the treatment of oncological, autoimmune, rare, and inflammatory diseases.

The total volume of investments will exceed 103 billion tenge, and the project will create more than 180 new permanent jobs.

The implementation of this project is of strategic importance for the development of Kazakhstan’s pharmaceutical industry and is aimed at expanding local production, forming a sustainable manufacturing base, and gradually replacing imports of socially significant medicines. In addition, part of the output is planned for export to the markets of the EAEU, CIS, as well as countries of the Middle East.

#Healthcare #Pharmaceuticals #President's instruction

• 
• 
• 
•